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Abstract
Background: The transcription factor, C/EBPbeta, is a key regulator of growth and differentiation
in the mammary gland. There are three different protein isoforms of C/EBPbeta. C/EBPbeta-1 and
-2 are transactivators, and differ by only 23 N-terminal amino acids present in beta-1 only. C/
EBPbeta-3 (LIP) lacks the transactivation domain and represses transcription. Elevated C/EBPbeta-
2 expression causes MCF10A normal human mammary epithelial cells to become transformed,
undergo an epithelial to mesenchymal transition (EMT), and acquire an invasive phenotype. C/
EBPbeta is a downstream transcriptional target of Ras signaling pathways and is required for Ras
transformation of some cell types. Ras signaling pathways are activated in mammary epithelial cells
by the ErbB receptor tyrosine kinase family. Therefore, we considered whether elevated C/
EBPbeta-2 expression would resemble ErbB RTK activation in MCF10A cells.
Results: We show that elevated C/EBPbeta-2 expression confers EGF-independent growth in
MCF10A mammary epithelial cells. However, MCF10A cells expressing C/EBPbeta-3 are not EGF-
independent, and high C/EBPbeta-3 or LIP expression is incompatible with growth. C/EBPbeta-2
overexpression disrupts the normal acinar architecture of MCF10A cells in basement membrane
cultures and induces complex multiacinar structures with filled lumen, similar to the consequences
of aberrant ErbB2 activation.
Conclusion: Given the ability of C/EBPbeta-2 to confer EGF-independent growth to mammary
epithelial cells as well as its capability for disrupting normal epithelial architecture and causing EMT,
it is worth considering whether inhibitors which target ErbB family signaling pathways could be less
effective in mammary epithelial cells with elevated nuclear C/EBPbeta-2 expression.
Introduction
The activation of tyrosine kinase receptors plays an impor-
tant role in the genesis of breast cancer. From the extensive
analysis of many breast tumors it is well established that
ErbB tyrosine kinase receptors, in particular ErbB2 and
ErbB1 (epidermal growth factor receptor, EGFR), often
become constitutively active in breast cancer as a result of
overexpression, or in the case of ErbB1, autocrine ligand
production or mutation (for reviews see [1-4]). Approxi-
mately 25% of invasive breast cancers exhibit ErbB2 gene
amplification and the rate of ErbB2 gene amplification or
protein overexpression in ductal carcinoma in situ (DCIS)
is the same or higher than in invasive cancers [2,3]. EGFR
and ErbB2 co-overexpression in breast tumors is associ-
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ated with resistance to endocrine therapies ([5,2] and ref-
erences therein). Recognizing the alterations in EGFR
family tyrosine kinase function galvanized the develop-
ment of one of the first approved targeted cancer thera-
peutics, Herceptin, an antibody inhibitor of ErbB2
(reviewed in [6]). The success of Herceptin and other ther-
apies targeting the ErbB receptor family in the treatment
of breast cancer patients has so far been mixed [7,8]. This
outcome likely reflects the complexity of ErbB receptor
tyrosine kinase (RTK) family signaling and the potential
to activate alternative pathways, for example, insulin-like
growth factor receptor (IGF-R) signaling ([9] and refer-
ences therein).
A common feature of receptor tyrosine kinases is that their
activation generates tyrosine-phosphorylated recognition
motifs for the binding of signaling proteins containing Src
homology 2 domains. The ErbB receptor tyrosine kinases
transmit proliferative signals to the nucleus via multiple
signaling pathways, including the Shc- and/or Grb2-acti-
vated Ras-Raf-MAPK pathway and phosphatidylinositol-
3-kinase (PI-3 K) pathways (reviewed in [1]). Ultimately
RTK signaling modulates the activity of transcription fac-
tors within the nucleus, leading to alterations in the pro-
gram of gene expression within the cell. Transcription
factors targeted by the ErbB receptor family are likely to
have key roles in controlling the growth and proliferation
of epithelial cells, given the essential role which altera-
tions in ErbB receptor function have on oncogenic trans-
formation.
Gene deletion studies have shown that the transcription
factor, C/EBPbeta, is in fact just such a master regulator of
growth and differentiation of the mammary gland
[10,11]. C/EBPbeta is a member of a family of basic-leu-
cine zipper transcription factors that play a decisive role in
the function of many cell types (reviewed in [12,13]). The
mammary epithelial cells (MECs) of C/EBPbeta null mice
fail to proliferate in response to hormonal signals at
puberty and during pregnancy, and the MECs fail to dif-
ferentiate in response to lactation-specific hormones
resulting in failure to lactate upon parturition [10,11].
Using BrdU labeling, Robinson et al. [10] demonstrated
that increased epithelial cell proliferation in early preg-
nancy and proliferation at late pregnancy stages were
strongly impaired in the absence of C/EBPbeta. Further-
more, no expression of β-casein or WAP mRNA was
detected in mammary tissue from mutant mice late in
pregnancy. Thus, these mice display a dual phenotype: a
defect in mammary epithelial cell proliferation in
response to hormonal stimulation at puberty or preg-
nancy, as well as a defect in epithelial cell differentiation
in response to lactation-specific hormones.
The production of multiple isoforms of C/EBPbeta in cells
may be one mechanism by which a single transcription
factor can regulate both differentiation and proliferation.
Three isoforms of C/EBPbeta can be produced in cells via
alternative translation initiation at 3 in frame
methionines [14,15]. C/EBPbeta-1 and -2 (also called
LAP* and LAP, respectively) are transactivators, and differ
by just 23 N-terminal amino acids present in beta-1 but
not beta-2 (value for human, chimp and bovine proteins,
21 aa in mouse, rat and chicken proteins and 22 aa in
Xenopus laevis). C/EBPbeta-3 (also called LIP) lacks the
N-terminal half of C/EBPbeta, including the transactiva-
tion domain, and therefore represses transcription.
Although many initially assumed that C/EBPbeta-1 and -
2 would be functionally redundant transactivators
because of their extensive similarity, this does not appear
to be the case. Only C/EBPbeta-1 (LAP* or LAP1) interacts
with the Swi/Snf chromatin-remodeling complex, an
interaction that requires the N-terminal amino acids
absent from C/EBPbeta-2 [16]. We have also recently
found that C/EBPbeta-1, but not -2, is sumoylated at
lysine 173, a modification that may uniquely direct C/
EBPbeta-1 to specific subnuclear locations and/or protein
partners [17]. The different expression patterns of C/EBP-
beta-1 and -2 also suggest non-overlapping functional
roles for the two transactivators. C/EBPbeta-1 is the only
isoform present in normal tissue from reduction mammo-
plasty [18]. However, 70% of invasive surgical primary
breast tumor samples have acquired a high level of C/EBP-
beta-2 expression, and C/EBPbeta-2 is the only transacti-
vator isoform expressed in breast cancer cell lines [18].
Recently, we have shown that MCF10A normal human
mammary epithelial cells, engineered to selectively over-
express C/EBPbeta-2, become transformed, undergo an
epithelial to mesenchymal transition (EMT), and acquire
an invasive phenotype [19]. MCF10A C/EBPbeta-2 cells
are anchorage-independent, form foci in soft agar, show
loss of junctional E cadherin localization, exhibit
cytoskeletal reorganization with actin stress fibers typical
of motile fibroblasts, express vimentin, and are invasive in
vitro [19].
C/EBPbeta is known to be phosphorylated by numerous
kinases [20-24] and thus is targeted by many signaling
pathways including those that activate the ERK and RSK
kinases. In fact, Zhu et al. [25] have recently reported that
C/EBPbeta is an essential mediator of skin tumorigenesis
involving oncogenic Ras signaling. C/EBPβ null mice are
completely refractory to carcinogen-induced skin tumors
involving mutant Ras. Because the ERK and RSK kinases
are downstream targets of the Shc- and/or Grb2-activated
Ras-Raf-MAPK pathways and phosphatidylinositol-3-
kinase (PI-3 K) pathways activated by ErbB receptor tyro-
sine kinases, it is possible that C/EBPbeta-2 is a down-Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
Page 3 of 17
(page number not for citation purposes)
Exogenous C/EBPbeta-2 expression confers EGF-independent growth in MCF10As Figure 1
Exogenous C/EBPbeta-2 expression confers EGF-independent growth in MCF10As. Micrographs of untreated (panels A and C) and C/
EBPbeta-2 overexpressing (panels B and D) MCF10A cultures are shown one (panels A and B) and two (panels C and D) days 
after growth in medium lacking EGF. Cells were plated on day 0 at 5 × 105 per 60 mm dish and the same location was imaged 
on both days. The bar represents 600 microns. Cell cycle profiles of control MCF10A(untreated), MCF10A cells infected with 
LZRS-Lac-Z virus (+ Beta-Gal), and MCF10A cells infected with LZRS-His-C/EBPbeta-2 virus (+ C/EBPbeta-2) were deter-
mined after growth in the presence or absence of EGF for 3 days. Results are shown as the mean of 4 separate experiments. 
Error bars indicate ± standard error of the mean (SEM). Solid black bars indicate the percentage of cells present in G0/G1, 
gray-filled bars the percentage in S-phase, and white-filled bars the percentage in G2/M. When compared to control MCF10A 
and MCF10A + Beta-Gal cell populations grown in the absence of EGF, the cell cycle distribution of MCF10A + C/EBPbeta-2 
grown under identical conditions was determined to be statistically significant (p < 0.0001 for G0/G1 and G2/M and p < 0.0085 
for S-phase). In contrast, there was no significant difference in the cell cycle distribution of MCF10A + C/EBPbeta-2 cells cul-
tured in the absence of EGF compared to any of the MCF10A-based cells grown in the presence of EGF.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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stream target of ErbB receptor tyrosine kinase signaling in
mammary epithelial cells. Here we demonstrate that
MCF10A cells, which are normally dependent on EGF for
growth, no longer require EGF when C/EBPbeta-2 is over-
expressed. It has been argued that C/EBPbeta-3 or LIP is
an important oncogenic mediator of EGF signaling
[26,27]. However, we find that LIP expression in MCF10A
cells does not confer EGF-independent growth. In fact,
overexpression of LIP is incompatible with growth and
the LIP-positive cells quickly disappear from the popula-
tion.
MCF10A cells, although immortal, are often used as a
model of normal glandular epithelium because they form
growth-arrested three-dimensional acinar structures when
grown in basement membrane cultures [28-30]. These
structures resemble the individual acinar units of polar-
ized epithelial cells surrounding a hollow lumen that
form the terminal ductal lobular units in the adult breast.
It is now well established that maintaining this well-
ordered epithelial architecture is crucial to maintaining a
differentiated state and the control of cell proliferation
[31]. The carcinogenic process that disrupts the hollow,
polarized architecture is mimicked by the expression of
activated ErbB2 receptors in MCF10A cells [29]. Activa-
tion of ErbB2 signaling in MCF10A acini reinitiates prolif-
eration and induces complex multiacinar structures with
filled lumen [29,49]. We show that overexpression of C/
EBPbeta-2 results in a strikingly similar disruption in the
3D architecture of MCF10A cells in basement membrane
cultures. Our data indicate that elevated C/EBPbeta-2 has
many of the same consequences as aberrant ErbB signal-
ing in mammary epithelial cells.
Results
C/EBPbeta-2 confers EGF-independent growth
We have previously described [19] the development of
MCF10A cells overexpressing C/EBPbeta-2 via infection
with a chimeric retrovirus encoding C/EBPbeta-2 (LZRS-
His C/EBPbeta-2). Expression of only the C/EBPbeta-2
isoform was achieved by deletion of amino acids 1–21 of
the rat protein. It is important to note that C/EBPbeta-3
cannot be translated from our C/EBPbeta-2 construct.
This is because expression of C/EBPbeta-3 depends upon
a small (9aa) evolutionarily conserved alternative open
reading frame (ORF) located before the second in frame
ATG of C/EBPbeta [14,15] that is deleted with the N-ter-
minal aa 1–21 truncation. Loss of this 9aa ORF is suffi-
cient to eliminate C/EBPbeta-3 expression [15].
As previously described, viable, non-adherent cells began
to accumulate in C/EBPbeta-2 overexpressing cultures
within 3 days post infection [19]. These non-adherent
cells can be subcultured and provide a non-clonal popu-
lation of cells overexpressing C/EBPbeta-2. To provide a
control population of cells, we also infected MCF10A cells
with a beta-galactosidase encoding retrovirus (LZRS-beta-
gal). Due to the high titer of the LZRS retroviral system, we
were able to obtain >95% infection of MCF10A cells with
the LZRS-beta-gal virus.
Typically, MCF10A cells, which are not transformed,
require EGF in the culture medium for growth. To analyze
the effect of C/EBPbeta-2 expression on EGF dependence,
we plated uninfected MCF10A cells or C/EBPbeta-2-
MCF10A cells at equal densities (5 × 105 per p60) in the
presence or absence of EGF on day 0. (Note that both cul-
tures are maintained in 5% horse serum, only the EGF has
been removed). Photomicrographs of the cultures 1 or 2
days later are shown in Figure 1A. Uninfected MCF10A
cells (panels A and C) are still very sparse after 2 days,
remaining essentially at the same density they were origi-
nally plated. In contrast, C/EBPbeta-2-MCF10A cells
(panels B and D) are able to proliferate in the absence of
EGF and the culture is approaching confluence 2 days
after plating. To confirm this observation we performed
cell cycle analyses on the cultures by FACS. As shown in
Figure 1B, a typical culture of MCF10A cells growing log-
arithmically in the presence of EGF contained 45% of the
cells in G0/G1 and 25% or 28% in S phase and G2/M,
respectively. Upon removal of EGF, the proportion of cells
in G0/G1 increased to 80%, indicating a substantial
growth arrest, consistant with the photomicrographs in
Figure 1A. Control infected cells expressing beta-gal
behaved similarly and were substantially growth arrested
upon removal of EGF from the medium. In contrast, there
was no significant change in the fraction of C/EBPbeta-2-
MCF10A cells in G0/G1 whether or not EGF was present
in the growth medium. The proportion of C/EBPbeta-2-
MCF10A cells in S or G2/M cells was also not perturbed by
EGF withdrawal. Therefore, we conclude that C/EBPbeta-
2 expression confers EGF-independent growth onto
MCF10A cells. In addition to cell cycle profiles being
unchanged, the doubling time of C/EBPbeta-2-MCF10A
cells was not different in the presence or absence of EGF
(data not shown).
EGF signaling network in C/EBPbeta-2 expressing cells is 
still EGF dependent
We considered that C/EBPbeta-2 might lead to the EGF-
independent growth of MCF10A cells by one of two gen-
eral mechanisms. First, C/EBPbeta-2 may be (or may be
able to substitute for) a key downstream transcriptional
target for EGF signaling in these cells. Once C/EBPbeta-2
is overexpressed, EGF signaling is no longer necessary for
growth. Alternatively, C/EBPbeta-2 may not reside in the
EGF signaling pathway, but may nonetheless be able to
upregulate one or more key components of the pathway,
in essence turning on the pathway in the absence of lig-
and. In the simplest instance, C/EBPbeta-2 could just leadMolecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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to overexpression of the EGF receptor itself. This mecha-
nism has in fact been reported for the transcription factor,
YY1, whose expression in MCF10A cells was recently
found to confer EGF-independent growth [50]. To inves-
tigate this possibility here, we evaluated the expression
level and phosphotyrosine status of the EGF receptor by
immunoblotting. We infected MCF10A cells with LZRS-
hisC/EBPbeta-2/IRES/GFP retrovirus and selected the
floating cells, which are all GFP positive cells with a high
level of C/EBPbeta-2 expression. A control population of
MCF10A cells expressing GFP only was generated by
infecting with an LZRS-IRES-GFP retrovirus and sorting
the GFP positive cells by FACS. As shown in Figure 2A,
withdrawal of EGF leads to a substantial decline in phos-
photyrosine 1173, the major autophosphorylation site of
the human EGF receptor [32], in both C/EBPbeta-2-
MCF10A cells and control GFP-MCF10A cells or unin-
fected MCF10A cells. The level of EGFR is also similar
among the three MCF10A cell populations; we found no
evidence that C/EBPbeta-2 leads to an increase in EGFR
expression as seen in Figure 2B. Thus, the EGF-independ-
ent growth of C/EBPbeta-2-MCF10A cells is not due to
upregulation of the EGF receptor or its phosphotyrosine
status.
To gain a broader profile of the phosphorylation status of
additional signaling molecules, we analyzed the phos-
phorylation state of a number of proteins in the ErbB sig-
naling cascade utilizing the immunoblot array technology
of Kinetworks (Kinexus Bioinformatics Corp, Vancouver,
British Columbia. Note: Because this was not a custom
screen, the phosphosites monitored are not limited to
EGF signaling). As shown in Figure 3A and presented
quantitatively in Table 1, when normal MCF10A cells are
grown in the presence of EGF, a number of phosphopro-
tein components of the EGF signaling network are present
as expected, including Shc (Y239/Y240) and ERK2 (T185/
Y187) as well as phosphoErbB2 (Y1139). Two additional
phosphotyrosine sites in the EGF receptor were present in
this screen, Y1148, a major binding site of Shc [33] and
Y1068, a binding site for Grb2 [34]. Withdrawal of EGF
from the MCF10A cells for 3 days resulted in a substantial
decline in both phosphoY1148 and Y1068, similar to that
observed for Y1173 in the EGF receptor in Figure 3.
PhosphoY1139 in ErbB2 is also strongly reduced in the
absence of EGF as are the Shc and ERK2 phosphorylation
sites profiled in this assay. These declines are typical of
what would be expected from the growth-arrested
MCF10A cells in the absence of EGF signaling. Remarka-
bly, although very similar declines in these phosphopro-
tein sites in the EGF signaling pathway were observed,
MCF10A cells expressing C/EBPbeta-2 continue to prolif-
erative without effect.
To confirm and extend the Kinexus phosphosite screen,
we performed immunoblots with individual antibodies in
the EGF signaling pathway from EGFR to ERK1/2. In this
set of experiments we prepared extracts from cells that had
been deprived of EGF for 48 hrs (Fig. 3B, lanes 1&3) or
subsequently stimulated with EGF for 30 min (Fig. 3B,
lanes 2&4). Once again we find that C/EBPbeta-2 expres-
sion does not change the total level of EGFR and both cell
types respond normally to EGF stimulation with strong
induction of tyrosine phosphorylation of the receptor on
Y1173 as shown. Although three phosphoMEK sites were
included in the Kinexus screen, the two serine residues at
positions 217 and 221 activated by Raf kinases were not.
We therefore probed for serine221 phosphorylation upon
EGF stimulation as shown in Fig. 3B. Phosphorylation of
serine221 in MEK1/2 was strongly induced in MCF10A
cells after EGF treatment (Fig. 3B, lanes 1&2) and expres-
sion of C/EBPbeta-2 in these cells did not alter this
response (Fig. 3B, lanes 3&4). We also directly confirmed
the activation of ERK1/2 seen in the Kinexus phospho-
screen by monitoring tyrosine 204 phosphorylation, one
of two targets for MEK1/2 phosphorylation of ERK1,2. As
shown in Fig. 3B, EGF stimulation of MCF10A cells
resulted in a substantial increase in Y204 phosphorylation
of p42ERK2 and a weaker, but detectable increase in
p44ERK1 Y204 phosphorylation. MCF10A cells express-
ing C/EBPbeta-2 exhibited the same increase in p42ERK2
Y204 phosphorylation, but phosphoY204 was undetecta-
ble in p44ERK1. The results of Fig. 3B coincide closely
with the Kinexus phosphoscreen for ERK1/1 (see Table 1,
bands C&D). Interestingly, analysis of total ERK1 and 2 in
the MCF10A-C/EBPbeta -2 cells suggests that the lack of
phosphoERK1 may be due to a constitutively lower level
of ERK1 in the MCF10A-C/EBPbeta-2 cells (see Fig. 3B,
EGFR is unaltered in C/EBPbeta-2 overexpressing MCF10As Figure 2
EGFR is unaltered in C/EBPbeta-2 overexpressing MCF10As. 
Uninfected MCF10A cells (lanes 1 & 2), sorted MCF10A cells 
infected with LZRS-GFP virus (lanes 3 & 4), and subcultured 
MCF10A cells infected with LZRS-His-C/EBPbeta-2-IRES-
GFP virus (lanes 5 & 6) were grown in the presence (lanes 1, 
3, and 5) or absence (lanes 2, 4, and 6) of EGF for 3 days. Cell 
extracts were subjected to 8% SDS PAGE and blotted with 
an antibody that specifically detect (A) phosphorylated tyro-
sine 1173 (pY1173 EGFR). The same blot was reblotted with 
an antibody that detects total EGFR for normalization (B).Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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EGF signaling network remains EGF-dependent in C/EBPbeta-2 overexpressing MCF10As Figure 3
EGF signaling network remains EGF-dependent in C/EBPbeta-2 overexpressing MCF10As. (A) Kinetworks™ phospho-site screen 
(KPSS) 2.1 immunoblot analyses of cell extracts prepared from uninfected control MCF10A cells and LZRS-His-C/EBPbeta-2 
overexpressing cells (C/EBPbeta2/MCF10A) grown in the presence or absence of EGF for 3 days. Each lane was incubated with 
a specific mixture of antibodies, and scans of the ECL signals detected with a multi-imager are shown. The identity of specific 
phosphoylated bands on tyrosine (Y), threonine (T), or Serine (S) residues are as indicated: A SrcY529, B EGFR Y1068, C 
ERK1 T202/Y204, D ERK2 T185/Y187, E EGFR Y1148, F FAK Y576, G Src Y418, H MEK2 T394, I IGFR Y1162/Y1163, J FAK 
S910, K Insulin R Y972, L CDK-1 T14/Y15, M IRS1 Y1179, N FAK Y577, O MEK1 S298, P1 Shc Y239/240 (66), P2 Shc Y239/
240 (52), P3 Shc Y239/240 (46), Q ErbB2 1139, R FAK S722, S MEK1 T292, T MEK1 T386. (B) Immunoblot analyses of whole 
cell extracts prepared from uninfected MCF10A cells (lanes 1 & 2), or MCF10A cells infected with LZRS-His-C/EBPbeta-2 virus 
(lanes 3 & 4) which were deprived of EGF in medium containing 0.5% serum for 45 hrs (lanes 1 & 3) and then stimulated with 
EGF (20 ng/ml) for 30 min (lanes 2 & 4). Protein samples were subjected to 8% SDS PAGE and blotted with an antibodies that 
specifically detect EGFR phosphorylated on tyrosine 1173, MEK1/2 phosphorylated on serine 221, or ERK1/2 phosphorylated 
on tyrosine 204 as well antibodies that detect total EGFR, total MEK1/2 or total ERK1/2 respectively.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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lanes 3,4). We do not know why C/EBPbeta-2 expression
would result in a decline in ERK1, although the cells obvi-
ously continue to proliferate despite the deficit. In any
case, we conclude that elevated C/EBPbeta-2 expression
does not activate EGF signaling pathways; rather, a high
level of this transcription factor bypasses reliance on these
signaling pathways.
C/EBPbeta-3 or LIP does not confer EGF-independent 
growth
Although C/EPBbeta-2 can induce EMT in MCF10A cells
in culture [19], it has also been argued that the repressor
isoform, C/EBPbeta-3 or LIP, is predominantly expressed
during proliferative cellular responses and is associated
with aggressive tumors [26,27]. We therefore asked
whether C/EBPbeta-3 could also confer EGF-independent
growth upon MCF10A cells. MCF10A cells were infected
with a chimeric LZRS retrovirus selectively encoding LIP,
LZRS-LIP-IRES-GFP, or a control retrovirus expressing
GFP only (LZRS-IRES-GFP). We also infected MCF10A
cells with LZRS-C/EBPbeta-2-IRES-GFP for direct compar-
ison. We initially analyzed the populations for GFP posi-
tive cells 3 days postinfection in normal growth medium
containing EGF. Both the GFP only and C/EBPbeta-2
expressing cells were >90% GFP positive, reflecting the
high titer of the LZRS system, whereas the LIP-expressing
cells were 65% GFP positive (Figure 4). At day 5 postinfec-
tion the percent of GFP positive LIP-expressing cells had
dropped to 50% and 10 days later (day 15 pi) it was down
to <10%. Meanwhile the GFP positive C/EBPbeta-2
expressing cells or GFP only cells remained relatively con-
stant at >90%. It is clear from Figure 4 that a high level of
LIP expression is incompatible with continued prolifera-
tion, even in the presence of normal growth medium con-
taining EGF.
We next attempted to generate a population of LIP-
expressing cells by infecting MCF10A cells with LZRS-LIP-
IRES-GFP and then immediately sorting the GFP-positive
cells by FACS. We reasoned that, after sorting, selecting for
cell growth would establish a population of cells express-
ing LIP at a level that was at least compatible with contin-
ued proliferation. We examined the level of LIP
expression at various intervals after sorting as shown in
the immunoblot in Figure 5. 1 week after sort (the earliest
time we had enough cells to prepare a whole cell extract)
T7 tag antibody detected strong hisLIP expression (hisLIP
migrates at approx. 25 kd, rather than 20 kd, due to the
epitope tag), although not quite as robust as we observe
with his-taggedC/EBPbeta-2 expressing cells shown in Fig.
5A, lane 5 for comparison. However, when we reexam-
ined the LIP-MCF10A cells at 21 days post sort, we could
no longer detect hisLIP expression (Fig. 5A, lane 3) with
the T7tag antibody at this exposure level. We conclude
Table 1: Summary of Kinetworks KPSS2.1 Phosphosite Screen.
Lane Band Protein /Epitope Normalized CPM




2 B EGFR Y1068 a 2392 1354 3143 1468
4 E EGFR Y1148 a 922 N/D 1759 N/D
15 Q ErbB2 Y1139 a 1641 324 3040 421
14 P1 Shc Y239/Y240 (66) a 223 N/D 79 N/D
14 P2 Shc Y239/Y240 (52) a 575 331 365 231
14 P3 Shc Y239/Y240 (46) a 209 N/D 181 N/D
8 H MEK2 T394 b 1376 1710 1964 1245
13 O MEK1 S298 a 765 2204 604 786
17 S MEK1 T292 c 783 785 643 443
19 T MEK1 T386 c 632 509 289 270
3 C ERK1 T202/Y204 a 125 N/D N/D N/D
3 D ERK2 T185/Y187 a 988 237 1189 282
9 I IGF1R Y1162/Y1163 a N/D 795 N/D N/D
10 K Insulin R Y972 a N/D 431 N/D N/D
12 M IRS1 Y1179 a 1006 N/D 1389 N/D
5FF A K  Y 5 7 6  a 653 1569 526 323
10 J FAK S910 b 978 393 940 730
12 N FAK Y577 a 485 768 754 727
16 R FAK S722 c 955 5996 1734 1360
7 G Src Y418 a 1258 842 1283 1138
1AS r c  Y 5 2 9 c 6954 8349 5425 8944
5 L CDK1 T14/Y15c 4591 1106 5284 2514
a, b, and c indicate a(n) stimulatory, unknown, or inhibitory effect on protein function, respectively.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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that continued proliferation of MCF10A cells in culture is
permissible only when LIP expression is drastically
reduced. When examined with anti-C/EBPbeta antibody
(Figure 5B), we found that the level of exogenous LIP was
reduced to approximately that of the endogenous LIP
expression in MCF10A cells 21 days post sort. However,
the cells expressing a low level of hisLIP were still depend-
ent on EGF for growth (Figure 5C). Thus, not only does
LIP not confer EGF-independent growth, but it is also
strongly growth inhibitory at the high expression level
shown in Figure 5. It may seem surprising then that a high
level of LIP has been associated with aggressive tumors. It
is well established that the longer isoforms of C/EBPbeta
are highly susceptible to proteolysis, giving rise to a rela-
tively protease resistant core that is the same size as LIP
[35,36]. From our data it is likely that aggressive breast
tumors initially may have contained high levels of C/EBP-
beta-2, which was converted to LIP during handling and/
or extract preparation.
C/EBPbeta-2 expression disrupts the acinar architecture of 
MCF10A cells in basement membrane cultures
ErbB2 expression in MCF10A cells has recently been used
to model the events in cancer progression that lead to the
destruction of the normal acinar architecture of glandular
epithelium within the mammary gland [29,30]. Activa-
tion of a chimeric ErbB2 receptor using a dimerizing lig-
and in MCF10A cells induces proliferation and mult-acini
formation when the cells are cultured in basement mem-
brane gels. We have used the matrigel overlay culture tech-
niques of Debnath et al. [49] to examine the three
dimensional growth of MCF10A cells expressing C/EBP-
beta-2 in basement membrane cultures. The morphology
of uninfected MCF10A cells, or MCF10A cells infected
with GFP only virus or C/EBPbeta-2-IRES-GFP virus are
shown in Figure 6. Uninfected MCF10A cells (A-D) form
compact acinar structures, which (as will be shown later
by confocal microscopy) consist of a single layer of polar-
ized epithelial cells surrounding a hollow lumen. Similar
morphology is observed in the MCF10A-GFP only cells. In
contrast, cells expressing C/EBPbeta-2 (panels I-L) form
large, irregular, multiacinar structures, very similar in
appearance to MCF10A cells with activated ErbB2 signal-
ing. MCF10A-C/EBPbeta-2 cells previously selected for
anchorage independent growth (panels M-P) also display
the irregular, multiacinar phenotype in 3D basement
membrane cultures.
To further examine the multiacinar structures we have
imaged them by confocal microscopy. In Figure 7, the
structures have been stained with either ethidium bro-
mide homodimer dye (nuclear dye, red fluorescence in
panels a and c) or phalloidin (F-actin, red fluorescence in
panels b and d). Dual imaging of green fluorescence from
GFP present in the cells (after retroviral infection) is also
shown in Figure 7. The hollow lumens within the com-
pact acinar structures formed by MCF10A cells are easily
visible in panels a and b of Figure 7. In contrast, interior
confocal imaging of the irregular, multicellular structures
formed by the C/EBPbeta-2-MCF10A cells shows the
solid, filled lumens of these structures (panels c and d)
This is strikingly apparent in Figure 8, where only the red
nuclear fluorescence from EtBR homodimer staining is
shown. The compact structure formed by MCF10A cells in
panel 8a is comprised of a single layer of well organized
epithelial cells surrounding the hollow lumen. Structures
formed by the C/EBPbeta-2-MCF10A cells (panels 8b and
8c) have an irregular multi-acinar architecture combined
with luminal filling. A complete reconstruction of the
structures imaged by confocal microscopy in Figures 7
and 8 are available as movie files in the supplementary
material (see additional file 1 for panel 7a, additional file
2 for panel 7b, additional file 3 for panel 7c, and addi-
tional file 4 for panel 7d. Likewise see additional file 5 for
panel 8a, additional file 6 for panel 8b and additional file
7 for panel 8c.)
LIP overexpression is incompatible with cell growth Figure 4
LIP overexpression is incompatible with cell growth. MCF10A 
cells were infected with LZRS-GFP virus (), LZRS-HisC/
EBPbeta-2-IRES-GFP virus (∆) or LZRS-HisLIP-IRES-GFP 
virus (❍ ) and monitored for maintainence of GFP expression 
for 3 weeks post infection. Results are shown as the mean 
percentage of GFP cells observed in 4–7 randomly selected 
microscopic fields per time point ± SEM. The loss of GFP 
expression observed in the LIP/GFP infected culture was 
determined to be very significant with a p value < 0.0001. 
Statistical analysis of the linear trend for the GFP only and C/
EBPbeta-2/GFP infected cell populations was not significant 
(p values > 0.05).Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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Discussion
C/EBPbeta-2 expression enables mammary epithelial cells
to proliferate in the absence of EGF signaling pathways in
monolayer cultures and to form irregular, multiacinar
structures with filled lumen in three-dimensional base-
ment membrane cultures. Muthuswamy et al. [29] have
previously shown that activation of ErbB2, but not ErbB1
(EGFR) via homodimerization of a chimeric receptor with
a dimerizing ligand, reinitiates proliferation and induces
luminal repopulation in epithelial acini in basement
Exogenous LIP is lost in growing MCF10A cultures Figure 5
Exogenous LIP is lost in growing MCF10A cultures. Cell extracts were prepared from uninfected MCF10A cells (lane 1), GFP posi-
tive cells sorted by flow cytometry (lanes 2, 3, & 4) infected with either LZRS-GFP virus (lane 2) or LZRS-HisLIP-IRES-GFP 
virus (lanes 3 & 4). The sorted cells were placed in culture and allowed to expand. Extracts were analyzed from cell samples 
collected at 7 days (lane 4) or 21 days (lanes 2,3) post sort. Cell extracts were also prepared from a floating subculture of 
MCF10A cells infected with LZRS-His-C/EBPbeta-2-IRES-GFP (lane 5) 12 days after the C/EBPbeta-2/GFP overexpressing sub-
culture was established. Western analyses of the extracts is shown probed with anti-T7 epitope tag antibody (A) or anti-C/
EBPbeta C-terminal antibody (B).Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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membrane cultures, although dimerization of either
receptor is sufficient to promote proliferation of MCF10A
cells in monolayer culture in the absence of EGF. In dis-
secting the requirements for luminal filling, Debnath et al.
[49] found that inhibiting apoptosis (by exogenously
expressing antiapoptotic Bcl family proteins) or enhanc-
ing proliferation (via cyclin D1 or HPV E7 overexpres-
sion) alone did not result in luminal filling. However, the
lumen was filled when oncogenes that enhance prolifera-
tion were coexpressed with those that inhibit apoptosis,
or when ErbB2, which induces both activities, was acti-
vated. Our results in Figs 6, 7, 8 would suggest that like
ErbB2, C/EBPbeta-2 may be able to both enhance prolif-
eration and decrease apoptosis resulting in luminal fill-
ing. In this regard, not only do C/EBPbeta knockout mice
fail to develop Ras-dependent skin papillomas in
response to carcinogens such as dimethylbenzanthracene,
but a large increase in apoptotic epidermal cells was
observed in carcinogen-treated C/EBPbeta-/- mice com-
pared to wt animals [25]. Thus, Zhu et al. [25] have pro-
posed that C/EBPbeta may promote the survival of
transformed keratinocytes. More recently, Wessells et al.
[37] have shown that Myc/Raf-transformed macrophages
require the transcription factor C/EBPbeta to prevent cell
death. Transformed C/EBPbeta-/- macrophages undergo
programmed cell death upon withdrawal of exogenous
hematopoietic growth factors. Ecotopic expression of C/
EBPbeta, but not LIP, restored growth factor independent
survival to transformed C/EBPbeta null macrophages.
Interestingly, C/EBPbeta-dependent regulation of insulin-
Morphology of MCF10A acini cultured on Matrigel basement membrane Figure 6
Morphology of MCF10A acini cultured on Matrigel basement membrane. Untreated MCF10A cells (A–D), MCF10A cells infected 
with LZRS-GFP virus (E–H), unselected MCF10A cells infected with LZRS-His-C/EBPbeta-2-IRES-GFP virus (I–L), and a floating 
subculture of MCF10A cells derived from the aforementioned LZRS-His-C/EBPbeta-2-IRES-GFP culture (M–P) were overlayed 
on Matrigel and cultured for 9 days. Light micrographs (A, C, D, E, G, I, K, M, & O) and the corresponding flurorescent images 
are provided to the left (B, F, H, J, L, N, & P). Since untreated MCF10A cells do not express GFP, only one fluorescent image 
(B) is provided to demonstrate background fluorescence. All cells were cultured at the same passage number and imaged at the 
same magnification. Bar represents 100 microns.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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like growth factor I (IGF-I) expression was shown to play
a critical role in the ability of these myeloid tumor cells to
escape apoptosis [37]. Thus, C/EBPbeta-2 inhibition of
apoptosis would be consistent with the ability of C/EBP-
beta to promote survival in other cell types.
It has been noted that the altered mammary epithelial
structures formed upon ErbB2 activation exhibit many of
the properties of early-stage epithelial tumors, including a
high level of proliferation, filling of the lumen, deposition
of a basement membrane, and the lack of invasive proper-
ties [38]. MCF10A cells with activated ErbB2 are not
anchorage independent, maintain E-cadherin adherens
junctions, do not invade basement membrane and are not
migratory. However, it has recently been found that TGF-
beta can cooperate with activated ErbB2 to induce migra-
tion and invasion of MCF10A cells [38]. In contrast to
MCF10A cells with activated ErbB2, MCF10A cells
expressing C/EBPbeta-2 have undergone an epithelial to
mesenchymal transition. The cells show loss of junctional
E cadherin localization, exhibit cytoskeletal reorganiza-
tion with actin stress fibers typical of motile fibroblasts
and express vimentin [19]. C/EBPbeta-2-MCF10A cells are
anchorage-independent, form foci in soft agar, and are
invasive in vitro, at least in the Boyden chamber assay
[19]. We do not, however, observe the stellate growth pat-
tern typical of invasive and migratory breast cancer cell
lines such as MDA231 when C/EBPbeta-2-MCF10A cells
are placed in 3D matrigel cultures (Figs. 6, 7, 8). It would
be interesting to determine if TGFbeta treatment of these
cultures would cooperate with C/EBPbeta-2 to induce the
invasive projections that are the hallmark of highly meta-
static breast cancer cell lines in 3D matrigel cultures.
We did not find that C/EBPbeta-2 confers EGF independ-
ence simply by increasing the level of EGF receptor or con-
ferring ligand independence to the receptor. When EGF is
withdrawn from C/EBPbeta-2-MCF10A cells, there is a
loss of phosphotyrosine sites on both ErbB2 and EGFR
just as is observed in the parental MCF10A cells. Down-
stream targets such as phosphorylated Shc, MEK1,2 and
ERK2 also decline. Yet, despite the lack of EGF signaling,
C/EPBbeta-2-MCF10A cells continued proliferating, with
no change in cell cycle profile. Although the majority of
phosphorylation sites profiled in the Kinexus screen
behaved similarly in the MCF10A or C/EBPbeta-2-
MCF10A cells, we did observe a few responses specific to
the MCF10A cells. For example, FAK phosphorylation on
S722 (band R) was strongly enhanced upon withdrawal of
EGF in the MCF10A cells only. However, there is little
information on the role of S722 FAK phosphorylation, so
this difference is difficult to interpret. MEK phosphoryla-
tion on S298 (band O) is also enhanced upon EGF with-
drawal from MCF10A cells, while little difference is
observed +/- EGF in the C/EBPbeta-2-MCF10A cells. S298
in MEK1 is targeted by p21-activated kinase (PAK) in
response to integrin signaling and stimulates the associa-
tion of MEK1 with ERK [39,40]. Perhaps MCF10A cells, in
the absence of EGF signaling, may try to compensate by
relying more heavily on integrin-mediated signaling. In
contrast, MCF10A-C/EBPbeta-2 cells, which are already
anchorage independent, do not show this response. How-
ever, a more comprehensive analysis of signaling interme-
diates would be necessary to confirm this interpretation.
Given the wealth of information that C/EBPbeta can be
phosphoryated by terminal kinases in EGF signaling path-
ways such as ERK2 and RSK [16,21-25], it is certainly plau-
sible that C/EBPbeta-2 could normally be a downstream
target of EGF signaling. In general, Ras-dependent phos-
phorylation of C/EBPbeta on Thr235 by the MAP (ERK)
kinases is thought to activate the transactivation capability
of C/EBPbeta. Nonetheless, our analysis indicates that
EGF signaling is not active in the absence of EGF in both
C/EBPbeta-2 overexpression disrupts three-dimensional aci- nar structure of MCF10A cells Figure 7
C/EBPbeta-2 overexpression disrupts three-dimensional acinar 
structure of MCF10A cells. MCF10A cells were infected with 
LZRS-GFP (A & B) or LZRS-His-C/EBPbeta-2-IRES-GFP virus 
(C & D), overlayed atop a layer of matrigel, and allowed to 
grow. After 19 days in culture, cells were fixed and stained 
with ethidium homodimer dye (A & C) to visualize nuclei 
(shown in red) or Alexa 594 cojugated phalloidin dye (B & D) 
to visualize f-actin distribution (shown in red). The GFP 
expression (shown in green) indicates infected cells (A–D). 
Images were analyzed by confocal microscopy and represent 
the equitorial cross sections of the acini. Bars represent 22.5 
microns.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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MCF10A and MCF10A-C/EBPbeta-2 cells. Thus, C/EBP-
beta-2 must be able to mediate the EGF-independent of
growth of MCF10A-C/EBPbeta-2 even in the absence of
phosphoryation by kinases such as ERK2. One possibility
is that C/EBPbeta-2 is overexpressed to a high level that
drives the necessary protein-protein interactions through
mass action, rendering phosphorylation at sites like T235
unnecessary. Alternatively, other kinases may substitute
for the lack of ERK activity. Clearly, although C/EBPbeta-
2 does not activate EGF signaling, we have not ruled out
that other, compensating signaling pathways could be
activated. It is important to note that this study was not
meant to decipher whether EGF signaling normally regu-
lates C/EBPbeta-2 function in MECs and how these mech-
anisms might be bypassed upon C/EBPbeta-2
overexpression. This is likely to be a complex situation
better left to future studies.
We did not find that C/EBPbeta-3 or LIP expression was
able to confer EGF-independent growth. In fact a high
level of LIP expression was incompatible with continued
proliferation in culture, since the initially GFP positive,
LIP-expressing cells rapidly disappeared from a mixed cul-
ture containing both infected and non-infected cells.
When we sorted and deliberately tried to expand the GFP
positive, LIP expressing cells, we found that the cell popu-
lation we obtained (i.e. growth selected) had strongly
reduced epitope-tagged LIP expression. It has been argued
that the transcription inhibitor LIP isoform is predomi-
nantly expressed during proliferative cellular responses
and is associated with aggressive tumors. Zahnow et al.
[29] have reported that LIP is overexpressed in 23% of
infiltrating ductal carcinomas specimens. However, our
own study on primary breast tumor samples found that
high grade, invasive mammary carcinomas showed signif-
icant C/EBP-2 expression, but no LIP was detected in any
of the samples [18]. LIP is known to be easily generated by
artifactual proteolysis of the larger isoforms. It has also
been reported that expression of LIP under the control of
the whey acidic promoter in the mouse mammary gland
results in the formation of hyperplastic tissue and carcino-
mas [27]. However, because the LIP transgene was not
epitope-tagged in these mice it is not possible to ascertain
transgene expression distinguished from any endogenous
LIP expression. Moreover, the level of LIP expression
(transgene or enodogenous) in the mammary tumors was
not actually examined.
The C/EBPbeta transactivator or LAP has long been
known for its role in the activation of differentiation-spe-
cific genes in hepatocytes, adipocytes and macrophages.
Therefore, the consequences of dominant-negative LIP
expression were initially thought to be inhibition of the
differentiation-promoting functions of the activator,
thereby facilitating proliferation. It has more recently
been appreciated that C/EBPbeta is a critical regulator of
cellular proliferation/survival as well. C/EBPβ-null mice
show profound defects in liver regeneration after partial
hepatectomy [22,41]. C/EBPbeta is an essential mediator
of skin tumorigenesis involving oncogenic Ras signaling
[25]; and, C/EBPbeta is essential for oncogenic transfor-
mation of myeloid/macrophage-like cells by mycand raf
[37]. Evidence has now accumulated that differentiation-
specific gene expression, to the extent that it requires chro-
matin-remodeling abilities [16], may be carried out by
LAP* (C/EBPbeta-1). Our data would suggest that the
growth-promoting role of C/EBPbeta is carried out in
large measure by C/EBPbeta-2. The effect of LIP expres-
sion very likely depends on which of the longer isoforms,
C/EBPbeta-1 or -2, is present in the cells. Unfortunately, it
can be extremely confusing to identify C/EBPbeta-1 and -
2 in immunoblots by their size or mobility, as it is easy to
misidentify a phosphorylated, and therefore slower
mobility, C/EBPbeta-2, as C/EBPbeta-1. Nonetheless, for
normal cells, where C/EBPbeta-1 is the predominant iso-
form [18], LIP expression may indeed disrupt differentia-
tion-specific gene functions and in doing so contribute to
proliferation. However, in cells where C/EBPbeta-2 is the
predominant or only transactivator isoform, antagonizing
the function of C/EBPbeta-2 by LIP expression leads to the
inhibition of cell growth demonstrated here.
Ectopic expression of C/EBPbeta-2 disrupts lumen formation Figure 8
Ectopic expression of C/EBPbeta-2 disrupts lumen formation. 
Additional equitorial cross sections of typical acinar structure 
observed in MCF10A + GFP cells (A) compared to MCF10A 
cells overexpressing C/EBPbeta-2 & GFP (B & C). Acini were 
fixed after 19 days in culture and their nuclei visualized by 
ethidium homodimer dye (red). Bars represent 11 microns.Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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Given the ability of C/EBPbeta-2 to confer EGF-independ-
ent growth to mammary epithelial cells as well as its capa-
bility for disrupting normal epithelial architecture and
causing EMT, it is worth considering whether aberrant C/
EBPbeta-2 expression could contribute to the resistance of
some breast cancers to targeted therapies such as Hercep-
tin. Unlike C/EBPbeta-1 or -3, C/EBPbeta-2 is found in
both the cytoplasmic and nuclear compartments of the
cell [18,42]. In fact in normal mammary epithelial cells,
C/EBPbeta-2 is primarily sequestered in the cytoplasm
[18]. Alterations in the cytoplasmic-nuclear trafficking of
C/EBPbeta-2 could result in elevated nuclear levels of this
transcription factor, as could overt overexpression and an
increase in nuclear levels by mass action. Unfortunately it
is not possible to quantitative C/EBPbeta-2 expression
without resorting to immunoblotting, because all availa-
ble antibodies to C/EBPbeta-2 would also recognize C/
EBPbeta-1. Immunoblotting is not always practical, and
the risk of artifactual isoform generation during prepara-
tion of cell or tissue lysates is ever present. Improved tools
for C/EBPbeta-2 detection are clearly needed to better
assess the contribution of this transcription factor to the




The previously characterized MCF10A human mammary
cell line [43,44] was obtained from the American Type
Culture Collection (ATCC) in Manassas, VA. Cells were
grown in a 1:1 mixture of Dulbecco's modified Eagle
medium (DMEM) and Ham's F12 containing 2.5 mM L-
glutamine and supplemented with 5% horse serum
(Sigma, St. Louis MO), 10 micrograms/ml recombinant
human insulin (GIBCO Invitrogen Corp., Grand Island,
NY) 0.5 micrograms/ml hydrocortisone, 10 ng/ml epider-
mal growth factor (EGF), 100 ng/ml cholera toxin, 50 U/
ml penicillin, and 50 micrograms/ml streptomycin, as
described previously [19]. Photographs of the cells were
taken with an Olympus DP12 microscope/digital camara
system. The phoenix-ampho packaging cell line devel-
oped by GP Nolan (Stanford University, Palo Alto, CA)
was obtained from the ATCC and maintained as previ-
ously described [19,45].
Cloning of recombinant retroviral constructs and virus 
preparation
The control LZRS-LacZ retroviral supernatants were gener-
ated by transfection of the phoenix-amphotropic packag-
ing cell line with the hybrid EBV/retroviral construct,
pLZRS-LacZ, as described previously [46]. The previously
described LZRS-GFP only, LZRS-His-C/EBPbeta-2, and
LZRS-His-C/EBPbeta-2-IRES-GFP viral supernatants were
generated in a similar manner as described previously
[19]. The bicistronic pLZRS-His C/EBPbeta-3-IRES-GFP
vector used to generate LZRS-His-C/EBPbeta-3-IRES-GFP
retrovirus was constructed in a multi-step protocol. First,
rat C/EBPbeta-3 (also known as LIP and p20 C/EBPbeta)
was excised from the previously described pRSETA LIP
construct [47] with BamHI and EcoRI. The resulting 575
bp C/EBPbeta-3 coding sequence was then ligated into the
similarly digested pcDNA3.1HisC expression vector (Inv-
itrogen Life Technologies, San Diego, CA). The LZRS-His-
C/EBPbeta-3 construct was generated by replacing the
LacZ coding sequences of pLZRS-LacZ with the 711 bp
His-tagged C/EBPbeta-3 fragment excised from pcDNA3.1
His C/EBPbeta-3 with HinDIII and NotI. Next, the His-
tagged C/EBPbeta-3 sequences were subcloned into
pIRES2-EGFP expression vector (Clontech, Palo Alto, CA).
This was accomplished by digesting pLZRS-His C/EBP-
beta-3 with EcoRI and BglII, and ligating the resulting 720
bp fragment into pIRES2-EGFP at the EcoRI and BamHI
sites. Lastly, the bicistronic pLZRS-His-C/EBPbeta3-IRES-
GFP construct was generated by replacing the LacZ coding
sequences of pLZRS-LacZ with the 2,036 bp His-C/EBP-
beta-3-IRES-GFP coding sequences from pHis-C/EBPbeta-
3-IRES-GFP at the EcoRI and NotI restriction sites.
Recombinant, amphotropic retroviral stocks were gener-
ated by transfecting the phoenix-ampho packaging cells
independently with each of the above-described LZRS-
based constructs as described previously [19,46]. Retrovi-
ral transduction and the establishment of floating C/EBP-
beta-2 over-expressing subcultures were also described
previously [19].
Flow cytometry
DNA cell cycle profiles of sub-confluent (50–60%) cul-
tures were determined by flow cytometry using a BD FAC-
Scan (Becton Dickinson, San Jose, CA). Subconfluent
cultures of MCF10A cells and their derivatives were
deprived of EGF for 72 hours. If the cells reached conflu-
ence during this time period (i.e MCF10A+C/EBPbeta-2
cells without EGF or the control cultures with EGF), the
cells were trypsinized and replated at an appropriate den-
sity to reach 50–60% confluence at the end of the 72 hr
period. All cultures were harvested at 72 hrs by trypsiniza-
tion and pelleting in the presence of 20% fetal bovine
serum at 500 × g for 7 minutes. Following quantification
on a hemocytometer, approximately 2 × 106 cells were
washed twice in cold phosphate-buffered saline (PBS) and
fixed in ice-cold 70% ethanol (ETOH) overnight. The
samples were then pelleted at 500 × g for 7 minutes and
washed twice with ice-cold PBS. Lastly, the cells were incu-
bated in a staining solution containing 0.1% (v/v) Triton
X-100, 2.5 mg/ml RnaseA, 2.0 mg/ml propidium iodide,
1 microM EDTA in 1 × PBS for 30–60 minutes at 4°C in
the dark. Data was collected using BD Cellquest software
(BD Biosciences Immunocytometry Systems, San Jose,
CA), and cell cycle modeling performed using Modfit soft-Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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ware (Verity Software House, Topsham, ME). The cell
cycle profile of each population was generated from DNA
content data collected from between 17,000 to 23,000
separate events.
In addition, fluorescence-activated cell sorting (FACS)
was performed on MCF10A cultures infected with either
LZRS-GFP only or LZRS-His-C/EBPbeta-3-IRES-GFP virus
to generate pure GFP-expressing populations. Infected
populations were trypsinized and pelleted in media con-
taining 20% FBS at 500 × g for 7 minutes. The cells were
then resuspended in DMEM/F12 media containing 0.5%
horse serum and filtered through a sterile 0.95 micron
nylon mesh (Small Parts Inc., Miami Lakes, FL) prior to
sorting with a BD FACSAria equipped with FACSDiva soft-
ware (Becton Dickinson, San Jose, CA). GFP-expressing
cells were collected under sterile conditions in DMEM/
F12 media containing 20% horse serum, 20 mg/ml gen-
tamycin, 200 U/ml penicillin and 200 mg/ml streptomy-
cin. After the sorted populations were expanded in cell
culture, whole cell lysates were prepared and analyzed on
immunoblots.
Cellular proliferation assays
MCF10A cells were infected 3 times with LZRS-GFP only,
LZRS-His-C/EBPbeta2-IRES-GFP, or LZRS-His-C/EBP-
beta-3-IRES-GFP virus and maintained as usual. Day 0 of
the time course was designated as the date of the final viral
infection. One day before imaging the cultures, approxi-
mately 1 × 104 cells were passed into a 6 cm dish and
allowed to grow overnight. The growth media was aspi-
rated and replaced with a layer of PBS immediately before
microscopic examination to minimize background fluo-
rescence from the phenol-red containing media. GFP-flu-
orescence and transmitted light images of the same
representative microscopic field were taken with a using a
Hamamatsu C5810 color CCD camera with a 10X/0.25 N
Plan Ph1 lens and GFP filter set on a Leica DMIRB
inverted microscope. The percentage of GFP positive cells
present in 4 to 7 randomly selected representative fields
was tabulated and used to calculate the mean percentage
of GFP positive cells per plate for each timepoint. All flu-
orescence images were collected under identical condi-
tions.
Statistics
Statistical analysis of cell cycle profiles was performed
using one-way analysis of variance (ANOVA) with Dunnet
Mulitple Comparisons post test utilizing Instat 3.0 for
Macs (Graphpad Software, San Diego, CA). Results were
calculated as the mean ± SE of 4 separate assays. Each
assay included modeled cell cycle profiles from a popula-
tion of between 17,000 to 23,000 cells. For analysis of cel-
lular proliferation, the percentage of GFP positive cells in
a sample was determined from overlapping transmitted
light and GFP-fluorescent images of the same microscopic
field. Results are expressed as the mean percent GFP posi-
tive cells ± SE from 4–7 representative microscopic fields
per sample and timepoint. The results were plotted as the
percentage of GFP positive cells maintained within each
population over a period of time. Statistical analysis of the
linear trend of each population was analyzed using
ANOVA and Instat 3.0 for Macs. In all instances, results
with p values <0.01 were considered significant and p val-
ues > 0.05 were not.
Immunoblot analysis
Comparative levels of activated human epidermal growth
factor receptor EGFR in specified MCF10A cultures grown
with or without epidermal growth factor (EGF) for 72
hours was determined by standard immunoblot analysis
as described previously [19]. In brief, whole cell lysates
(WCLs) were prepared from 50–75% confluent 10 cm
dishes by scraping into a chilled solution containing pro-
tease and phosphatase inhibitors as previously described
[18]. Relative protein concentrations were determined
using Protein Assay Reagent (BioRad Laboratories, Her-
cules, CA) as per the manufactures' instructions. Equiva-
lent amounts of total protein were loaded and separated
on an 8% SDS-PAGE. Proteins were transferred to an
Immobilon P filter and processed as described previously
[18]. To detect phosphoEGFR (Y1173), the blot was incu-
bated overnight at 4°C in 0.5% NFDM-TBS-T with 1
microgram/ml anti-phospho-EGFR antibody (clone 9H2,
Upstate Cell Signaling Solutions, Charlottesville, VA) and
detected with goat-anti-mouse horse-radish peroxidase
(HRP)-conjugated secondary antibody (Promega, Madi-
son, WI) in 0.5% NFDM-TBS-T. For detection of total
EGFR, the blot was stripped using Re-blot Plus mild anti-
body stripping solution (Chemicon International Inc.,
Temecula, CA), probed with a 1: 1000 dilution of anti-
EGFR antibody (Upstate), and detected with 1:1000 dilu-
tion of biotinylated rabbit anti-sheep IgG (Vector Labs,
Burlingame, CA) followed by incubation with peroxidase-
conjugated streptavidin (Jackson ImmunoResearch Labs,
West Grove, PA). For analysis of EGF signaling, WCLs
were prepared from specified MCF10A cultures with or
without treatment for 30 min with 20 ng/ml EGF after
maintaining the cells for 45 hrs in growth medium as
described above except containing 0.5% horse serum and
no EGF. After analysis by 8% SDS-PAGE, duplicate immu-
noblots were probed with anti-EGF receptor or anti-phos-
phoEGFR (Y1173) as described above or anti-ERK-1 (sc-
94, Santa Cruz) or anti-phospho ERK (sc-7383, Santa
Cruz). Two blots were stripped using Re-blot Plus mild
antibody stripping solution and reprobed with anti-MEK-
1 (07–641, Upstate) or antiphospho MEK (S221, Cell Sig-
naling) antibodies. Blots were detected with a 1:5000
dilution of the appropriate goat anti-mouse or goat anti-
rabbit secondary antibodies (Cell Signaling).Molecular Cancer 2005, 4:43 http://www.molecular-cancer.com/content/4/1/43
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Kinexus Bioinformatics Corporation (51, Vancouver, Brit-
ish Columbia, Canada) performed Kinetworks™ bio-
source phospho-site screen (KPSS 2.1) western blot
analyses on WCLs prepared from MCF10A cultures treated
similarly to those described above [48]. In brief, 350
micrograms of WCL protein were separated by SDS-PAGE,
transferred to a thin membrane and, using a 20 lane
multiblotter apparatus, probed with a mixture of primary
antibodies that react with a distinct subset of phospho-
specific proteins of distinct molecular mass.
Quantification of the immunoreactive bands on the
Kinetworks blots (trace quantity) with ECL detection was
performed with a Bio-Rad Fluor S Max Imager and Bio-
Rad Quantity One software.
Three-dimensional overlay growth assays
In order to assess the three-dimensional growth properties
of MCF10A cells and their retrovirally transduced deriva-
tives, cells were grown according to the three-dimensional
overlay method described previously [30]. In brief, an 8-
well chambered slide was coated with a 2 mm thick layer
of growth factor reduced Matrigel, a reconstituted base-
ment membrane obtained from BD Discovery Labware
(Bedford, MA). A single cell suspension of 5,000 cells per
well was seeded atop the solidified layer of Matrigel and
then overlayed with Assay Medium (DMEM/F12 contain-
ing 2% Horse Serum, 10 micrograms/ml insulin, 0.5
micrograms/ml hydrocortisone, 100 ng/ml cholera toxin)
containing 2% Matrigel and 5 ng/ml EGF. Cells were
grown in a humdified incubator with 5% CO2 and refed
with Assay Medium containing 2% Matrigel and 5 ng/ml
EGF every 4 days. Transmitted light and epifluorescence
micrographs were acquired using a Hamamatsu C5810
color CCD camera with a 10X/0.25 N Plan Ph1 lens and
GFP filter set on a Leica DMIRB inverted microscope.
Immunofluorescence acquisition and image analysis
MCF10A cells and their retrovirally transduced derivatives
were cultured on basement membrane as described
above. After 19 days in three-dimensional culture, the aci-
nar structures were fixed and immunostained as described
previously with minor modifications [30]. Specifically,
acini were fixed with 2% paraformaldehyde in 1 × PBS for
20 minutes at RT, permeabilized with PBS containing
0.5% Triton X-100 for 10 minutes at 4°C, and rinsed three
times with PBS/Glycine (130 mM NaCl, 7 mM Na2HP04,
3.5 mM NaH2P04, and 100 mM Glycine) at RT for 10 min-
utes. The samples were then blocked with 200 microliters
per well of IF Buffer (130 mM NaCl, 7 mM NaN3, 0.1%
BSA, 0.2% Triton X-100, 0.05% Tween-20) and 10% nor-
mal goat serum (Jackson ImmunoResearch Labs) for 2
hours at RT. To visualize nuclei, samples were stained with
1 micromolar final concentration of ethidium
homodimer-2 (EthD-2) (Molecular Probes, Eugene OR)
for 15 minutes at RT. To visualize F-actin distribution,
samples were stained with Alexa 594-conjugated phalloi-
din (Molecular Probes) using1 unit in 200 microliters of
PBS per well for 15 minutes at RT. Samples were then
washed twice with 1 × PBS at RT for 10 minutes, the cham-
bers removed, and mounted in fresh Prolong Antifade rea-
gent (Molecular Probes). Confocal images were acquired
with an LSM510 confocal microscope using a Plan-
Apochromat 20x/0.75 or Fluar 10x/0.5 objective (Carl
Zeiss, New York, NY). The 20× lens was used for all images
except figure 7C that required the extra working distance
of the 10× lens to visualize the thick cell mass. Ethidium
homodimer-2 (red) fluorescence was excited at 543 nm
and emission detected through an LP585 barrier filter.
Alexa 594 phalloidin (red) fluorescence was excited at 543
nm and emission detected through an LP585 barrier filter.
GFP (green) fluorescence was excited at 488 nm and emis-
sion detected through a BP505–550 barrier filter.
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Six optical sections of acini comprised of MCF10A cells infected with 
LZRS-GFP virus show the cell nuclei stained with ethidium homodimer-
2 (red) and enhanced GFP expression (green). Image planes progress 
from the surface of the sphere (Supp. 7a1), downward toward the center 
(Supp. 7a3), to the opposite surface (Supp. 7a6). Sections are imaged 
every 9 microns.




Eighteen optical sections of acini comprised of MCF10A cells infected with 
LZRS-GFP virus illustrate f-actin organization stained with Alexa 594 
conjugated phalloidin (red) and enhanced GFP expression (green). Image 
planes progress from the focal plane near the surface (Supp 7b1), down-
ward toward the center (Supp 7b9), to the opposite surface (Suppl 7b18). 
Sections are imaged every 3 microns.
Click here for file
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Eight optical sections of acini comprised of MCF10A cells infected with 
LZRS-His-C/EBPbeta-2-IRES-GFP virus show the cell nuclei stained with 
ethidium homodimer-2 (red) and enhanced GFP expression (green). 
Image planes progress from the surface of the sphere (Supp 7c1), down-
ward toward the center (Supp. 7c4), to the opposite surface (Supp. 7c8). 
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of f-actin organization stained with Alexa 594-conjugated phalloidin 
(red) and enhanced GFP expression (green). Image planes progress from 
the focal plane near the surface (Supp 7d1), downward toward the center 
(Supp 7d8), to the opposite surface (Supp 7d16). Sections are imaged 
every 3 microns.
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Image planes progress from the focal plane near the surface (Supp 8a1), 
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8a11). The cells express GFP (not shown).
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opposite surface (Supp 8b16). Although not shown, the cells also express 
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ium homodimer-2 (red). Image planes progress from the focal plane near 
the surface (Supp 8c1), downward toward the center (Supp 8c10), to the 
opposite surface (Supp 8c20). Although not shown, the cells also express 
GFP.
Click here for file
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